Why the study?
Does the combination of candesartan and rosuvastatin reduce atherosclerosis and inflammatory marker expression in Apo-E knockout mice?
Does the combination of candesartan and rosuvastatin reduce atherosclerosis and inflammatory marker expression in Apo-E knockout mice?
The combination of candesartan and rosuvastatin additively reduces atherosclerosis and completely blocks CD40 and MMPs upregulation in Apo-E knockout mice.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in atherosclerosis models; leaves open translation to human therapy.
Chen et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: